Italian Start-up CellPly Snares $2.8M Seed Investment | GenomeWeb

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Italian Angels for Growth, Zernike Meta Ventures, and Atlas Seed made the investment into Bologna, Italy-based CellPly in order to support the firm's completion of its diagnostics platform, which is being developed to allow clinicians to assess in vitro a patient's cellular response to cancer treatments, such as chemotherapy and monoclonal antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.